CRVS vs CUBE · $1.04B cap vs P/E 25, rev $1.07B
Corvus Pharmaceuticals Inc (CRVS) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
Corvus Pharmaceuticals Inc (CRVS) is a biotechnology company listed on US.
CubeSmart (CUBE) is a reit - industrial company listed on US.
CRVS does not have a complete income-statement cache yet.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
CRVS currently screens at market cap $1.04B. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the CRVS and CUBE stock pages for the full models.
Not investment advice.